181 related articles for article (PubMed ID: 37587328)
21. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].
Werner RA; Bengel FM; Derlin T
Radiologe; 2020 May; 60(5):413-420. PubMed ID: 32052116
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.
Barrio M; Czernin J; Fanti S; Ambrosini V; Binse I; Du L; Eiber M; Herrmann K; Fendler WP
J Nucl Med; 2017 May; 58(5):756-761. PubMed ID: 28082438
[TBL] [Abstract][Full Text] [Related]
23.
Binderup T; Knigge U; Johnbeck CB; Loft A; Berthelsen AK; Oturai P; Mortensen J; Federspiel B; Langer SW; Kjaer A
J Nucl Med; 2021 Jun; 62(6):808-815. PubMed ID: 33067340
[TBL] [Abstract][Full Text] [Related]
24. Limited role of carbidopa-assisted
Imperiale A; Averous G; Helali M; Taieb D; Pessaux P; Goichot B; Addeo P; Bachellier P
Ann Nucl Med; 2019 Sep; 33(9):697-707. PubMed ID: 31214959
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and Treatment of Lung Neuroendocrine Neoplasms: Somatostatin Receptor PET Imaging and Peptide Receptor Radionuclide Therapy.
Park H; Subramaniam RM
PET Clin; 2023 Apr; 18(2):223-231. PubMed ID: 36585338
[TBL] [Abstract][Full Text] [Related]
26. Cardiac Metastases in Neuroendocrine Tumors: 68Ga-DOTATATE PET/CT With Cardiac Magnetic Resonance Correlation.
Polk SL; Montilla-Soler J; Gage KL; Parsee A; Jeong D
Clin Nucl Med; 2020 Apr; 45(4):e201-e205. PubMed ID: 32049725
[TBL] [Abstract][Full Text] [Related]
27. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
28. Multimodal Imaging of 2-Cycle PRRT with
Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
[TBL] [Abstract][Full Text] [Related]
29. Comparison of gallium-68 somatostatin receptor and
Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
[TBL] [Abstract][Full Text] [Related]
30. [Theranostics for Well and Moderately Differentiated GEP-NEN].
Hartrampf P; Werner R; Buck A
Zentralbl Chir; 2022 Jun; 147(3):249-255. PubMed ID: 35705086
[TBL] [Abstract][Full Text] [Related]
31. Comparison of [
Chen D; Yang S; Chen J; Li T; Liu Y; Zhao X; Zhang T; Xu M; Wang H; Zhao K; Su X
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2420-2431. PubMed ID: 36971805
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of
Ma H; Kan Y; Yang JG
Acta Radiol; 2021 Sep; 62(9):1217-1228. PubMed ID: 32985224
[TBL] [Abstract][Full Text] [Related]
33. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
[TBL] [Abstract][Full Text] [Related]
34. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.
Werner RA; Lapa C; Ilhan H; Higuchi T; Buck AK; Lehner S; Bartenstein P; Bengel F; Schatka I; Muegge DO; Papp L; Zsótér N; Große-Ophoff T; Essler M; Bundschuh RA
Oncotarget; 2017 Jan; 8(4):7039-7049. PubMed ID: 27705948
[TBL] [Abstract][Full Text] [Related]
35. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.
Dadgar H; Jafari E; Ahmadzadehfar H; Rekabpour SJ; Ravanbod MR; Kalantarhormozi M; Nabipour I; Assadi M
Ann Endocrinol (Paris); 2023 Feb; 84(1):45-51. PubMed ID: 36126757
[TBL] [Abstract][Full Text] [Related]
36. State-of-the-Art Hybrid Imaging of Neuroendocrine Neoplasms.
Ambrosini V; Fortunati E; Fanti S; Ursprung S; Asmundo L; O'Shea A; Kako B; Lee S; Furtado FS; Blake M; Goiffon RJ; Najmi Z; Hesami M; Murakami T; Domachevsky L; Catalano OA
J Comput Assist Tomogr; 2024 Apr; ():. PubMed ID: 38518197
[TBL] [Abstract][Full Text] [Related]
37. The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience.
Das S; Pineda G; Goff L; Sobel R; Berlin J; Fisher G
Cancer Imaging; 2018 Dec; 18(1):47. PubMed ID: 30522522
[TBL] [Abstract][Full Text] [Related]
38. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
39. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-
Galgano SJ; Iravani A; Bodei L; El-Haddad G; Hofman MS; Kong G
AJR Am J Roentgenol; 2022 May; 218(5):767-780. PubMed ID: 34985313
[TBL] [Abstract][Full Text] [Related]
40. Molecular imaging Theranostics of Neuroendocrine Tumors.
Fortunati E; Bonazzi N; Zanoni L; Fanti S; Ambrosini V
Semin Nucl Med; 2023 Jul; 53(4):539-554. PubMed ID: 36623974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]